74 related articles for article (PubMed ID: 27648841)
21. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
Goto K; Endo M; Kusumoto M; Yamamoto N; Ohe Y; Shimizu A; Fukuoka M
Cancer Sci; 2016 Dec; 107(12):1837-1842. PubMed ID: 27714941
[TBL] [Abstract][Full Text] [Related]
22. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
[TBL] [Abstract][Full Text] [Related]
23. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
24. Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Moiseyenko FV; Moiseyenko VM; Aleksakhina SN; Chubenko VA; Volkov NM; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Ivantsov AO; Venina AR; Preobrazhenskaya EV; Mitiushkina NV; Iyevleva AG; Imyanitov EN
Oncol Res Treat; 2016; 39(10):605-614. PubMed ID: 27710972
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.
Suzuki S; Shimazaki J; Morishita K; Koike N; Harada N; Hayashi T; Suzuki M
Mol Clin Oncol; 2016 Oct; 5(4):391-394. PubMed ID: 27699032
[TBL] [Abstract][Full Text] [Related]
26. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer.
Yin C; Ma G; Rong Y; Kong P; Yang Q; Jiang C; Liao F; Zhang B; He W; Xia L
J Cancer; 2016; 7(13):1901-1906. PubMed ID: 27698931
[No Abstract] [Full Text] [Related]
27. Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches.
Huang WJ; Chen WW; Zhang X
Oncol Lett; 2016 Oct; 12(4):2283-2288. PubMed ID: 27698790
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea.
Tremblay G; Majethia U; Breeze JL; Kontoudis I; Park J
Clinicoecon Outcomes Res; 2016; 8():485-493. PubMed ID: 27698565
[TBL] [Abstract][Full Text] [Related]
29. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Leighl NB; Rizvi NA; de Lima LG; Arpornwirat W; Rudin CM; Chiappori AA; Ahn MJ; Chow LQ; Bazhenova L; Dechaphunkul A; Sunpaweravong P; Eaton K; Chen J; Medley S; Poondru S; Singh M; Steinberg J; Juergens RA; Gadgeel SM
Clin Lung Cancer; 2017 Jan; 18(1):34-42.e2. PubMed ID: 27686971
[TBL] [Abstract][Full Text] [Related]
31. Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.
Dominguez C; Tsang KY; Palena C
Cell Death Dis; 2016 Sep; 7(9):e2380. PubMed ID: 27685624
[TBL] [Abstract][Full Text] [Related]
32. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
[TBL] [Abstract][Full Text] [Related]
33. Oral Bisphosphonates and Improved Survival of Breast Cancer.
Rennert G; Pinchev M; Gronich N; Saliba W; Flugelman A; Lavi I; Goldberg H; Fried G; Steiner M; Bitterman A; Landsman K; Rennert HS
Clin Cancer Res; 2017 Apr; 23(7):1684-1689. PubMed ID: 27683176
[No Abstract] [Full Text] [Related]
34. Population-Based Patterns and Factors Associated With Underuse of Palliative Systemic Therapy in Elderly Patients With Metastatic Colon Cancer.
Chan M; Hugh-Yeun K; Gresham G; Speers CH; Kennecke HF; Cheung WY
Clin Colorectal Cancer; 2017 Jun; 16(2):147-153. PubMed ID: 27670894
[TBL] [Abstract][Full Text] [Related]
35. Plasma levels of trastuzumab in gastric cancer: Case report.
González-García J; Alonso-Alvarez B; Nazco-Casariego GJ; Batista-López N; Guttiérrez-Nicolás F
J Oncol Pharm Pract; 2017 Dec; 23(8):635-637. PubMed ID: 27664112
[TBL] [Abstract][Full Text] [Related]
36. The role of ADAM17 in tumorigenesis and progression of breast cancer.
Shen H; Li L; Zhou S; Yu D; Yang S; Chen X; Wang D; Zhong S; Zhao J; Tang J
Tumour Biol; 2016 Sep; ():. PubMed ID: 27658778
[TBL] [Abstract][Full Text] [Related]
37. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Huang CW; Yeh YS; Ma CJ; Tsai HL; Chen CW; Huang MY; Lu CY; Wu JY; Wang JY
Chemotherapy; 2017; 62(1):80-84. PubMed ID: 27654129
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
